Examining Gossamer Bio Inc (GOSS)’s cash flow and debt position

In the latest session, Gossamer Bio Inc (NASDAQ: GOSS) closed at $0.90 down -7.47% from its previous closing price of $0.97. On the day, 1376945 shares were traded.

Ratios:

For a deeper understanding of Gossamer Bio Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 5.94 and its Current Ratio is at 5.94. In the meantime, Its Debt-to-Equity ratio is 3.38 whereas as Long-Term Debt/Eq ratio is at 3.15.

On July 27, 2023, UBS Downgraded its rating to Neutral which previously was Buy and also lowered its target price recommendation from $8 to $1.25.

Insider Transactions:

Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Mar 27 ’24 when Hasnain Faheem sold 23,172 shares for $1.16 per share. The transaction valued at 26,773 led to the insider holds 120,293 shares of the business.

Giraudo Bryan sold 6,430 shares of GOSS for $7,431 on Mar 27 ’24. The COO/CFO now owns 92,737 shares after completing the transaction at $1.16 per share. On Mar 27 ’24, another insider, Christian Waage, who serves as the EVP, Tech Ops and Admin of the company, sold 6,430 shares for $1.16 each. As a result, the insider received 7,430 and left with 585,934 shares of the company.

Stock Price History:

Over the past 52 weeks, GOSS has reached a high of $1.88, while it has fallen to a 52-week low of $0.45.

Shares Statistics:

A total of 225.41M shares are outstanding, with a floating share count of 188.87M. Insiders hold about 16.27% of the company’s shares, while institutions hold 79.44% stake in the company.

Earnings Estimates

There are Canada Goose Holdings Inc. Subo different market analysts currently analyzing its stock. The consensus estimate for the next quarter is $2.19, with high estimates of $0.90 and low estimates of $3.13.

Analysts are recommending an EPS of between $Healthcare and $Technology for the fiscal current year, implying an average EPS of $Technology.

Most Popular

[the_ad id="945"]